Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients.

Jim Joseph, Farzana Ganjifrockwala, Grace George

Open access · hybridAbstract read

In one paragraph

Article in Oxidative medicine and cellular longevity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact, top 81% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

Serum lipoprotein(a), and plasminogen activator inhibitor-1 in uncomplicated type 2 diabetes mellitus: a case-control study.Annals of medicine and surgery (2012) · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jim JosephDivision of Medical Biochemistry, Department of Human Biology, Faculty of Health Sciences, Walter Sisulu University, Mthatha Campus, Nelson Mandela Drive, Mthatha 5100, South Africa.ORCID 0000-0001-7404-4178

Farzana GanjifrockwalaDivision of Medical Biochemistry, Department of Human Biology, Faculty of Health Sciences, Walter Sisulu University, Mthatha Campus, Nelson Mandela Drive, Mthatha 5100, South Africa.ORCID 0000-0003-2647-8056

Grace GeorgeDivision of Medical Biochemistry, Department of Human Biology, Faculty of Health Sciences, Walter Sisulu University, Mthatha Campus, Nelson Mandela Drive, Mthatha 5100, South Africa.ORCID 0000-0002-4662-720X

Walter Sisulu University · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein (a) (Lp(a)) which is a low-density lipoprotein-like particle containing apo(a) is considered as an emergent cardiovascular risk factor. Type 2 diabetes mellitus (T2DM) is associated with a two- to threefold increase in the risk of cardiovascular disease (CVD). The aim of this study was to investigate the levels of Lp(a) in Black South African T2DM patients and its association with other metabolic factors. 67 T2DM patients and 48 healthy control participants were recruited for the cross-sectional study. The Lp(a) level was determined by ELISA and the result was analyzed using SPSS. The Lp(a) level in diabetics was found to be significantly increased (

Indexed as

Black PeopleAntioxidantsCase-Control StudiesC-Reactive ProteinDiabetes Mellitus, Type 2FemaleHumansLipoprotein(a)Lipoproteins, LDLMaleMiddle AgedSouth AfricaTriglyceridesAntioxidantsC-Reactive ProteinLipoprotein(a)Lipoproteins, LDLoxidized low density lipoproteinTriglycerides

Identifiers

PMID27833702

DOI10.1155/2016/5743838

PMCPMC5090092

OpenAlexW2532907478

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.